- Delays in beginning neoadjuvant chemotherapy (NACT) did not adversely affect OS in women with stages I-III triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Why this matters
- This is the first study of the effect of time to initiation of NACT and long-term outcome.
- Results are reassuring to patients with aggressive disease who delay NACT up to 6 months after diagnosis.
- Retrospective cohort (n=12,806) of women with stage I-III breast cancer in the US National Cancer Database.
- Patients with hormone receptor (HR)-positive/HER2- disease were excluded because of lower NACT use and better prognosis.
- Funding: None disclosed.
- Breast cancer subtypes included TNBC (50%), HR+/HER2+ disease (30%), and HR−/HER2+ disease (20%).
- Median time from diagnosis to NACT was 4.3 (range, 0-25.6) weeks.
- Median follow-up was 36 months.
- When time to NACT initiation was a continuous variable, no relationship was found between OS and TNBC (HR, 1.00; P=.71) or HER2+ cancer (HR, 0.98; P=.26).
- When time to NACT initiation was dichotomized, no relationship was found between OS and:
- Delay >4 weeks (vs + disease (HR, 0.91; P=.37).
- Delay >3 weeks (vs
- Retrospective, observational design.